Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

CSL (CSLN) Stock Price & Analysis

CSLN Stock Chart & Stats

MX$2,080.00MX$0.00(0.00%)
At close:
MXN 2,000MXN 2,500MXN 3,000MXN 3,50010 Jan30 Jul24 Sep19 Jan
Day’s Range
MXN 2,080.00 - MXN 2,080.00
52-Week Range
MXN 2,077.68 - MXN 2,414.77
Previous Close
MXN 2,080.00
Volume
0
Average Volume (3M)
0
Market Cap
MXN 1.27T
Enterprise Value
MXN 70.67B
Total Cash (Recent Filing)
MXN 1.51B
Total Debt (Recent Filing)
MXN 10.89B
Price to Earnings (P/E)
―
Beta
-0.09
Next Earnings
Feb 09, 2027 (Est.)
EPS Estimate
74.67
Next Dividend Ex-Date
N/A
Dividend Yield
2.32%

Bulls Say, Bears Say

Bulls Say

Strong Cash Generation

Positive operating cash flow despite the reported loss demonstrates that CSL’s core businesses continue to convert activity into funding. This supports dividends, buybacks, investment in capacity and product development, while providing resilience through portfolio remediation.

Transformation Savings

Savings delivered ahead of plan can create a durable improvement in the cost base if execution continues. Reinvesting part of those savings into commercial and R&D initiatives may strengthen efficiency while preserving funding for longer-term growth.

Specialty Product Momentum

Growth from recently launched and specialty therapies broadens CSL’s future product base beyond mature franchises. Successful uptake can improve mix and support recurring demand in serious medical conditions, helping offset pressure in challenged products.

Bears Say

Large Impairments And Statutory Loss

The scale of impairments and the statutory loss indicate that previously recorded asset values and earnings expectations have been materially reset. This weakens recent earnings quality, reduces equity support and raises the burden on management to restore returns.

Structural Vifor Decline

Vifor’s challenges reflect durable portfolio and market-access pressures rather than a brief sales fluctuation. Generic competition, lost reimbursement support and the TAVNEOS authorization change can reduce revenue and make recovery dependent on replacement products.

Albumin Market Pressure

The albumin decline shows that pricing and reimbursement pressure in an important market is affecting an established therapy franchise. Continued market-value pressure could constrain revenue quality and margins even if volumes stabilize, limiting recovery in the medium term.

CSL News

CSLN FAQ

What was CSL’s price range in the past 12 months?
CSL lowest stock price was Mex$2077.68 and its highest was Mex$2414.77 in the past 12 months.
What is CSL’s market cap?
CSL’s market cap is Mex$1.27T.
When is CSL’s upcoming earnings report date?
CSL’s next earnings report is estimated for Feb 09, 2027 (not yet confirmed), which is in 99 days.
How were CSL’s earnings last quarter?
CSL released its earnings results on Aug 17, 2026. The company reported Mex$42.178 earnings per share for the quarter, missing the consensus estimate of Mex$43.951 by -Mex$1.773.
Is CSL overvalued?
According to Wall Street analysts CSL’s price is currently Undervalued.
Does CSL pay dividends?
CSL does not currently pay dividends.
What is CSL’s EPS estimate?
CSL’s EPS estimate is 74.67.
How many shares outstanding does CSL have?
CSL has 479,884,280 shares outstanding.
What happened to CSL’s price movement after its last earnings report?
CSL reported an EPS of Mex$42.178 in its last earnings report, missing expectations of Mex$43.951. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of CSL?
Currently, no hedge funds are holding shares in MX:CSLN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology